My watch list  

10 Current news about the topic cell culture technology


Top award for 3D cell culture pioneer, Stefan Przyborski, of Reinnervate Ltd


Prof Stefan Przyborski, CSO and founder of Reinnervate Ltd, has been recognised with a top award from the Royal Society of Chemistry. The Rita and John Cornforth award 2012 recognises Prof. Przyborski’s leadership and inter-disciplinary work at the boundaries of physical chemistry and biology, ...


Reinnervate completes expansion into new purpose-built facility at NETPark


Reinnervate announced its expansion into a new purpose-built research and production facility at NETPark near Sedgefield, UK. The move to the circa 10,000 square foot facility has enabled reinnervate to begin commercial production of its alvetex® 3D cell culture technology in readiness for its ...


Takeda Announces New Initiative in Cell Culture-Based Influenza Vaccines


Takeda Pharmaceutical Company Limited announced that it has received an official notice from the Pharmaceutical Development Support Center with regard to the granting of a government subsidy for which it had applied. Takeda was notified in writing on July 6 of this decision, and the company has ...


Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility

Facility designed to supply 150 million doses of pandemic vaccine within 6 months of influenza pandemic declaration


Novartis officially inaugurated the US's first ever large-scale flu cell culture vaccine and adjuvant manufacturing facility in Holly Springs, North Carolina. The facility is a result of a partnership between Novartis and the US Department of Health and Human Services (HHS). It is the first of ...


ExcellGene and Kühner achieved milestone in development of novel 250 Liter mammalian cell culture bioreactors


ExcellGene SA and Adolf Kühner AG announced that they achieved an important milestone in the development of a cell culture technology for scale up and manufacturing from suspension cultured mammalian cells. As part of a long-term partnership the two companies disclose the successful conclusion ...


Nobilon receives European GMP approval for production of Influenza vaccines for clinical trials


Nobilon International obtained a European Good Manufacturing Practice (GMP) approval to produce human influenza vaccines for use in clinical trials. The approval was granted recently by the Dutch Ministry of Public Health following a mandatory inspection of the company's premises in Boxmeer, the ...


Crucell Updates Progress in Scale-up of Cell-culture-based Influenza Vaccine Programs


Leiden. Crucell N.V. announced that it has received a milestone payment of EUR 1 million (US$ 1.2 million) from sanofi pasteur, the vaccines business of the sanofi-aventis group, in acknowledgement of the progress the company has made in development of novel influenza products using Crucell´s ...


Akzo Nobel's Nobilon and BioDiem sign influenza vaccine tie-up


Nobilon International, part of Akzo Nobel's Pharma group, has entered into a licensing agreement with Australian pharmaceutical development company BioDiem Ltd. Under the agreement, Nobilon - which was set up by Akzo Nobel in 2003 as a strategic move into the human vaccines market - will pay a ...


Solvay and Petrovax combine ground breaking skills to produce new flu vaccines in Russia

Solvay Pharmaceuticals cell line to feed Petrovax production unit in Moscow


Solvay Pharmaceuticals and Petrovax Pharm announce the signing of a contract to co-operate on the construction of a facility which will produce new generation flu vaccines near Moscow. Petrovax will own and operate the new factory, which is expected to come on stream in 2006. The production will ...


VaxGen Forms Joint Venture to Build Manufacturing Facilities in California and South Korea

Facilities Designed to Support Potential Regulatory Approval and Commercial Manufacture of VaxGen's AIDS Vaccine


BRISBANE, Calif. and SEOUL – February 25, 2002 – VaxGen, Inc. and a group of South Korean investors today announced the formation of a joint venture, which will invest approximately $120 million to build and operate a facility in Incheon, South Korea, to manufacture VaxGen’s AIDS vaccine. The ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE